Ritlecitinib 50 mg

DRUG4 trials

Sponsors

Pfizer

Conditions

Alopecia AreataChronic Spontaneous UrticariaHealthy

Phase 1

A Target Occupancy Study With Ritlecitinib.

CompletedNCT05128058

Start: 2021-10-22End: 2022-01-14Updated: 2023-11-13

Phase 2

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

RecruitingNCT07219615

PfizerChronic Spontaneous Urticaria

Start: 2025-10-30End: 2027-04-23Target: 200Updated: 2026-06-17

Phase 3

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

RecruitingNCT06873945

PfizerAlopecia Areata

Start: 2025-04-01End: 2028-03-19Target: 674Updated: 2026-09-18

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

RecruitingNCT07733765

PfizerAlopecia Areata

Start: 2026-07-30End: 2028-04-26Target: 336Updated: 2026-09-10

Related Papers

Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.

2025-10-14

Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model

The AAPS Journal2024-01-2415 citations